| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1047926720 |
| P356 | DOI | 10.2165/00002018-199614010-00003 |
| P698 | PubMed publication ID | 8713485 |
| P2093 | author name string | T R Pedersen | |
| J A Tobert | |||
| P2860 | cites work | Scandinavian simvastatin study (4S) | Q93871926 |
| Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia | Q28334603 | ||
| Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy | Q28335369 | ||
| Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) | Q29547825 | ||
| Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration | Q29619529 | ||
| Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group | Q29619842 | ||
| Rhabdomyolysis associated with lovastatin and erythromycin use. | Q33558924 | ||
| Atherosclerosis: inhibition of regression as therapeutic possibilities | Q33611394 | ||
| Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers | Q34346101 | ||
| Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials | Q35170262 | ||
| Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations | Q35180196 | ||
| Should there be a moratorium on the use of cholesterol lowering drugs? | Q35820088 | ||
| Cholesterol reduction yields clinical benefit. A new look at old data | Q36697948 | ||
| The pathogenesis of coronary artery disease and the acute coronary syndromes (1). | Q36728740 | ||
| By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? | Q36884264 | ||
| Why sources of heterogeneity in meta-analysis should be investigated | Q36888653 | ||
| Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). | Q38507399 | ||
| Controversies in meta-analysis: the case of the trials of serum cholesterol reduction | Q39522433 | ||
| Efficacy and long-term adverse effect pattern of lovastatin | Q39539391 | ||
| Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension | Q40569218 | ||
| A review of clinical trials comparing HMG-CoA reductase inhibitors | Q40630809 | ||
| Plasma protein binding displacement interactions--why are they still regarded as clinically important? | Q40753816 | ||
| Long-term experience with pravastatin in clinical research trials | Q40889607 | ||
| Retardation and arrest of progression or regression of coronary artery disease: a review | Q40909464 | ||
| Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease | Q40913054 | ||
| Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia | Q40923088 | ||
| Prognostic significance of progression of coronary atherosclerosis | Q41083474 | ||
| Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease | Q41193242 | ||
| The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. | Q41965669 | ||
| Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program | Q42276628 | ||
| Cholesterol lowering does have a role in secondary prevention | Q42394455 | ||
| Doubts about preventing coronary heart disease | Q42766516 | ||
| Misleading meta-analysis | Q42841765 | ||
| Lower patients' cholesterol now | Q42856073 | ||
| Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation | Q43842693 | ||
| Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE) | Q44555886 | ||
| Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) | Q44966192 | ||
| Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia | Q48832403 | ||
| Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia. | Q48844225 | ||
| Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study | Q48852622 | ||
| Clinical experience with lovastatin | Q48926162 | ||
| Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. | Q50595888 | ||
| Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. | Q51125145 | ||
| Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. | Q51596506 | ||
| Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group. | Q53019532 | ||
| Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia | Q57840115 | ||
| The effects of pravastatin on hyperlipidemia in renal transplant recipients | Q67735533 | ||
| Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study | Q67922812 | ||
| Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants | Q67969157 | ||
| Health policy on blood cholesterol. Time to change directions | Q68032416 | ||
| Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations | Q68096185 | ||
| Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia | Q68167241 | ||
| Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B | Q68564239 | ||
| Platelet function in hyperlipoproteinemia | Q68676427 | ||
| Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia | Q69485577 | ||
| The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering | Q70309308 | ||
| Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia | Q70529738 | ||
| A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group | Q70620194 | ||
| Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV | Q70677844 | ||
| Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) | Q70736889 | ||
| Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. The Simvastatin Pravastatin Study Group | Q70776599 | ||
| Lowering cholesterol with drugs and diet | Q71759109 | ||
| Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S) | Q71774511 | ||
| Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group | Q71857151 | ||
| Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole | Q71965502 | ||
| Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study | Q72005574 | ||
| ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collabor | Q72028603 | ||
| Fluvastatin with and without niacin for hypercholesterolemia | Q72042653 | ||
| Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group | Q72200868 | ||
| Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS) | Q72220309 | ||
| Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients | Q72221073 | ||
| Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S) | Q72226519 | ||
| Lowering cholesterol levels in patients with coronary heart disease. The LIPID Study Management Committee | Q72226919 | ||
| Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia | Q72235675 | ||
| The actions of lovastatin on platelet function and platelet eicosanoid receptors in type II hypercholesterolaemia. A double-blind, placebo-controlled, prospective study | Q72252560 | ||
| Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. European Study Group | Q72279374 | ||
| Combination therapy with HMG CoA reductase inhibitors and gemfibrozil: practical or perilous? | Q72313364 | ||
| Preventing heart attack and death in patients with coronary disease | Q72331372 | ||
| President's page: expanding the role of the American College of Cardiology | Q72351054 | ||
| Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease | Q72431695 | ||
| The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion | Q72431698 | ||
| Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries | Q72560592 | ||
| Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) | Q72566674 | ||
| Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin | Q72681316 | ||
| A Randomized Multicenter Trial Comparing and Efficacy of Simvastatin and Fluvastatin | Q73468708 | ||
| A Comparison of the Tolerability and Efficacy of Lovastatin 20 mg and Fluvastatin 20 mg in the Treatment of Primary Hypercholesterolemia | Q73468729 | ||
| Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia | Q88116001 | ||
| P433 | issue | 1 | |
| P921 | main subject | coronary artery disease | Q844935 |
| P304 | page(s) | 11-24 | |
| P577 | publication date | 1996-01-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal | |
| P478 | volume | 14 |
| Q73194084 | A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study |
| Q44704634 | A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d |
| Q38895987 | A systematic review of interventions to improve adherence to statin medication: What do we know about what works? |
| Q44079578 | ACC/AHA/NHLBI clinical advisory on the use and safety of statins |
| Q87657491 | Anti-hypercholesterolemic effect of Pistacia lentiscus fatty oil in egg yolk-fed rabbits: a comparative study with simvastatin |
| Q37765562 | Atorvastatin: safety and tolerability |
| Q34074683 | Cerivastatin: the low-dose HMG-COA reductase inhibitor |
| Q41742293 | Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials |
| Q39446259 | Choosing the most appropriate treatment for stable angina. Safety considerations |
| Q33646070 | Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols |
| Q43568694 | Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease |
| Q77390980 | Economic implications of lipid-lowering trials: current considerations in selecting a statin |
| Q29617910 | Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials |
| Q47671221 | Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group |
| Q43568677 | Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis |
| Q34114367 | FDA adverse event reports on statin-associated rhabdomyolysis |
| Q34236671 | HMG-CoA reductase inhibitors |
| Q71273781 | HMG-CoA reductase inhibitors: issues in assessing their benefits in coronary heart disease |
| Q37855801 | Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins |
| Q24569666 | Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial |
| Q57116735 | LJ-1888, a selective antagonist for the A3 adenosine receptor, ameliorates the development of atherosclerosis and hypercholesterolemia in apolipoprotein E knock-out mice |
| Q34315710 | Lipid disorders in patients with type 2 diabetes. Meeting the challenges of early, aggressive treatment |
| Q73459941 | Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group |
| Q38056781 | Lovastatin for adult patients with dengue: protocol for a randomised controlled trial |
| Q34478635 | Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? |
| Q28219266 | Optimal lipid modification: the rationale for combination therapy |
| Q35127790 | Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy |
| Q41742306 | Profiling risk and new therapeutic interventions: looking ahead |
| Q34382555 | Rhabdomyolysis and HMG-CoA reductase inhibitors |
| Q44161783 | Robotic inhibition assay for determination of HMG-CoA reductase inhibitors in human plasma. |
| Q42653850 | STATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease. Simvastatin Treats Asians to Target |
| Q34306983 | Selenoprotein synthesis and side-effects of statins |
| Q34372227 | Simvastatin: a review |
| Q37636347 | Statins and amyotrophic lateral sclerosis--the level of evidence for an association |
| Q73048669 | The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day |
| Q34636135 | The safety of statins in clinical practice |
| Q73919585 | Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: absolute levels or extent of lowering? |
Search more.